




- (51) International Patent Classification:  
A61K 51/08 (2006.01) C07B 59/00 (2006.01)
- (21) International Application Number:  
PCT/EP2014/078609
- (22) International Filing Date:  
18 December 2014 (18.12.2014)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
1322456.3 18 December 2013 (18.12.2013) GB
- (71) Applicant: GE HEALTHCARE LIMITED [GB/GB];  
Amersham Place, Little Chalfont Buckinghamshire HP7 9NA (GB).
- (72) Inventors: ENGELL, Torgrim; GE Healthcare AS, Nycoveien 2, Postboks 4220 Nydalen, N-0401 Oslo (NO). GETVOLDSEN, Gareth, Simon; GE Healthcare Limited, The Grove Centre, White Lion Road, Amersham Buckinghamshire HP7 9LL (GB). MEJGER, Andreas, Richard; GE Healthcare AS, Nycoveien 2, Postboks 4220 Nydalen, N-0401 Oslo (NO). KHAN, Imtiaz, Ahmed; GE Healthcare Limited, The Grove Centre, White Lion Road, Amersham Buckinghamshire HP7 9LL (GB). NAIRNE, Robert, James; GE Healthcare Limited, The Grove Centre, White Lion Road, Amersham Buckinghamshire HP7 9LL (GB). MCROBBIE, Graeme; GE Healthcare Limited, The Grove Centre, White Lion Road, Amersham Buckinghamshire HP7 9LL (GB).
- (74) Agents: BANNAN, Sally et al.; GE Healthcare Limited, Pollards Wood, Nightingales Lane, Chalfont St Giles Buckinghamshire HP8 4SP (GB).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
- Published:  
— with international search report (Art. 21(3))

(54) Title: RADIOTRACER COMPOSITIONS AND METHODS

Figure 2: Cassette Configuration.



(57) Abstract: The present invention relates to the field of radiopharmaceuticals for in vivo imaging, in particular to radiotracer compositions which comprises <sup>18</sup>F-labelled c-Met binding peptides. The invention provides said compositions, as well as associated automated methods of preparation and cassettes.

## Radiotracer Compositions and Methods.

### Field of the Invention.

The present invention relates to the field of radiopharmaceuticals for *in vivo* imaging, in particular to radiotracer compositions which comprises <sup>18</sup>F-labelled c-Met binding peptides. The invention provides said compositions, as well as associated automated methods of preparation and cassettes.

### Background to the Invention.

10 Hepatocyte growth factor (HGF), also known as scatter factor (SF), is a growth factor which is involved in various physiological processes, such as wound healing and angiogenesis. The high affinity interaction of HGF interaction with its receptor (c-Met) is implicated in tumour growth, invasion and metastasis.


15 c-Met has been shown to be involved in tumour growth, invasion and metastasis in many human cancers of epithelial origin. c-Met is expressed by most carcinomas and its elevated expression relative to normal tissue has been detected in cancers of: lung, breast, colorectal, pancreatic, head and neck, gastric, hepatocellular, ovarian, renal, glioma, melanoma and a number of sarcomas. In colorectal carcinoma (CRC), over-  
20 expression of c-Met has been detected in dysplastic aberrant crypt foci, the earliest pre-neoplastic lesions of the disease. In head and neck squamous cell cancer, c-Met is reportedly expressed or overexpressed in roughly 80% of primary tumours. In prostate cancer metastasis to bone, c-Met was reported overexpressed in over 80% of bone metastasis.

25

Under normal conditions, c-Met is expressed on epithelial cells and activated in a paracrine fashion, by mesenchymally derived HGF. The activation of c-Met in normal cells is a transient event and is tightly regulated. In tumour cells, however, c-Met can be constitutively active. In cancer, aberrant c-Met stimulation can be  
30 achieved through c-Met amplification/over-expression, activating c-Met mutations (e.g. structural alterations) and acquisition of autonomous growth control through creation of autocrine signalling loops. In addition, a defective down-regulation of the c-Met receptor will also contribute to aberrant c-Met expression in the cell membrane. While the over-expression of c-Met is HGF dependent (autocrine/paracrine),

structural alterations caused by mutations are HGF independent (e.g. loss of extracellular domain).

Poethko *et al* [J.Nucl.Med., 45(5), 892-902 (2004)] disclose a method of radiolabelling peptides with the radioisotope  $^{18}\text{F}$ , wherein an aminoxy-functionalised peptide is condensed with [ $^{18}\text{F}$ ]-fluorobenzaldehyde to give a labelled peptide having an oxime ether linkage as follows:




Schottelius *et al* [Bioconj.Chem., 19(6), 1256-1268 (2008)] further developed the method of Poethko *et al*. Schottelius *et al* use an aminoxy-functionalised peptide wherein the amine of the aminoxy group is protected with an *N*-Boc (Boc = *tert*-butyloxycarbonyl) protecting group. The desired aminoxy-functionalised peptide is generated *in situ* in the presence of [ $^{18}\text{F}$ ]-fluorobenzaldehyde *via* deprotection of the *N*-Boc group at acidic pH (pH = 2) at 75 °C. Schottelius *et al* used a 5-fold molar excess of the Boc-protected precursor, because the deprotection was not quantitative under the reaction conditions.

Mezo *et al* [J.Pept.Sci., 17, 39-46 (2010)] describe some of the problems associated with the above oxime ligation chemistry of Boc-protected aminoxy-functionalised peptides. Thus, it is known that the Boc-aminoxy reagent can acylate formed Boc-protected aminoxy-peptide, leading to undesirable by-products. It is also known that the reactivity of the free aminoxy group of the functionalised peptide is high towards carbonyl compounds. Consequently, unwanted condensation can occur with any adventitious aldehydes or ketones present either in the reaction mixture or in any


subsequent purification steps. Such aldehydes or ketones could be traces of acetone present in the solvents used, or formaldehyde (e.g. from plasticizers). Mezo *et al* are interested in solving this problem for both the conjugation of anti-cancer drugs and of [<sup>18</sup>F]-fluorobenzaldehyde to peptides. Mezo *et al* solve the problem by carrying out the deprotection of the Boc-aminoxy peptide in the presence of a tenfold molar excess of free (aminoxy)acetic acid (Aoa) as a ‘carbonyl capture agent’. The deprotected aminoxy-peptide and excess Aoa is then lyophilised and stored at 4 °C. Immediately prior to the oxime ligation reaction, the lyophilised mixture is reconstituted, and excess Aoa is separated by HPLC or Sep-Pak plus C18 cartridge. Mezo *et al* provide an example in which non-radioactive (i.e. <sup>19</sup>F) 4-fluorobenzaldehyde is conjugated to an aminoxy-functionalised somatostatin peptide using this technique. Mezo *et al* do not provide any data on <sup>18</sup>F-radiolabelling.

WO 2012/022676 discloses an imaging agent which comprises an <sup>18</sup>F-radiolabelled 18 to 30-mer c-Met binding cyclic peptide (cMBP) of Formula I:



where:

cMBP is of Formula II:



where Q is the amino acid sequence (SEQ-1):



wherein X<sup>1</sup> is Asn, His or Tyr;

X<sup>2</sup> is Gly, Ser, Thr or Asn;

X<sup>3</sup> is Thr or Arg;

X<sup>4</sup> is Ala, Asp, Glu, Gly or Ser;

X<sup>5</sup> is Ser or Thr;

X<sup>6</sup> is Asp or Glu;

and Cys<sup>a-d</sup> are each cysteine residues such that residues a and b as well as c and d are cyclised to form two separate disulfide bonds;

A and A' are independently any amino acid other than Cys, with the proviso that at least one of A and A' is present and is Lys;

x and y are independently integers of value 0 to 13, and are chosen such that [x + y] = 1 to 13;

$Z^1$  is attached to the N-terminus of cMBP, and is H or  $M^{IG}$ ;

$Z^2$  is attached to the C-terminus of cMBP and is OH,  $OB^c$ , or  $M^{IG}$ ,

where  $B^c$  is a biocompatible cation;

each  $M^{IG}$  is independently a metabolism inhibiting group which


5 is a biocompatible group which inhibits or suppresses *in vivo* metabolism of the cMBP peptide;

wherein cMBP is labelled at the Lys residue of the A or A' groups with  $^{18}F$ .

WO 2012/022676 also discloses that the imaging agents may be used as

10 pharmaceutical compositions, wherein said compositions preferably comprises one or more radioprotectants preferably chosen from: ethanol; ascorbic acid; *para*-aminobenzoic acid (i.e. 4-aminobenzoic acid or pABA); gentisic acid (i.e. 2,5-dihydroxybenzoic acid), and salts of such acids with a biocompatible cation.


15 WO 2012/072736 discloses the use of alternative protecting group chemistry for the aminoxy groups of functionalised biomolecules. The protected aminoxy group is of formula:



wherein:

20  $R^1$  and  $R^2$  are independently chosen from  $C_{1-3}$  alkyl,  $C_{1-3}$  fluoroalkyl or  $C_{4-6}$  aryl.

US 2013/0209358 A1 discloses that  $^{18}F$ -fluciclatide can undergo radiolysis at high radioactive concentration:



25

$^{18}F$ -fluciclatide

US 2013/0209358 A1 reports that  $^{18}\text{F}$ -fluciclatide is not stabilised by ethanol, and that ascorbic acid is not ideal for automated radiosyntheses, but that 4-aminobenzoic acid (or salt thereof) is effective. US 2013/0209358 A1 teaches that the  $^{18}\text{F}$ -fluciclatide is first prepared, and then the radioprotectant is added.

5

There is therefore still a need for improved methods of preparing and purifying  $^{18}\text{F}$ -labelled c-Met peptide radiotracers, to give high purity compositions suitable for radiopharmaceutical applications *in vivo*.

10

#### The Present Invention.

The present inventors have identified and analysed the radiochemical impurities present in  $^{18}\text{F}$ -labelled c-Met targeting peptides, and how the levels of such impurities vary over time. That investigation led to the understanding that in-process radiolysis during attempted purification was the root cause of the RCP (radiochemical purity) problems.

This can be understood as follows. Thus, the radiotracers of the present invention, when purified and formulated for *in vivo* use, are present at a radioactive concentration (RAC) of approximately 500 to 700 MBq/mL (0.5 to 0.7 GBq/mL).

The radiotracer may exhibit satisfactory stability, or minimal degradation under such RAC conditions. That is, however, obtained from a crude reaction mixture, where the RAC is in the range of ca. 10 to 15 GBq/mL. Furthermore, the present inventors have established that, during purification (i.e. at the end of the radiosynthesis), approximately 45 GBq of radioactivity is concentrated in a tight band on the chromatography column in a volume of less than 1 mL. That leads to an in-process RAC during purification of >45 GBq/mL. Since the purification can take 10-15 minutes, the risk of in-process radiolysis is high.


The present invention provides methods for stabilising the radiotracers whilst carrying out purification, and hence also provides improved radioactive yields and compositions. The present invention provides a method of purification of a radiotracer which comprises an  $^{18}\text{F}$ -labelled c-Met targeting peptide. It is in fact both a method of purification and a method of radiostabilisation (i.e. stabilising against

radioactive degradation). Thus, by preventing in-process radiodegradation during purification, the present invention also improves the radiochemical purity, since impurities which might otherwise be generated are suppressed. The method also provides an improved radiochemical yield, since in-process losses during chromatography are minimised.

#### Detailed Description of the Invention.

In a first aspect, the present invention provides a radiopharmaceutical composition which comprises:

(i) a radiotracer which comprises a c-Met binding peptide of Formula I labelled with  $^{18}\text{F}$ :



(ii) a radioprotectant which comprises 4-aminobenzoic acid, or a salt thereof with a biocompatible cation;

(iii) a biocompatible carrier which comprises aqueous ethanol having an ethanol content of 0.1 to 10 % v/v;

in a form suitable for mammalian administration;

where:

cMBP is the c-Met binding peptide having the amino acid sequence:

Ala-Gly-Ser-Cys<sup>a</sup>-Tyr-Cys<sup>c</sup>-Ser-Gly-Pro-Pro-Arg-Phe-Glu-Cys<sup>d</sup>-Trp-Cys<sup>b</sup>-Tyr-Glu-Thr-Glu-Gly-Thr-Gly-Gly-Gly-Lys

wherein Cys<sup>a-d</sup> are each cysteine residues such that residues a and b as well as c and d are cyclised to form two separate disulfide bonds;

$\text{Z}^1$  is attached to the *N*-terminus of cMBP, and is  $\text{M}^{\text{IG}}$ ;

$\text{Z}^2$  is attached to the *C*-terminus of cMBP and is  $\text{M}^{\text{IG}}$ ,

$\text{M}^{\text{IG}}$  is independently a metabolism inhibiting group which is a biocompatible group which inhibits or suppresses *in vivo* metabolism of the cMBP peptide;

the Lys residue of the cMBP is labelled with  $^{18}\text{F}$ .

The term “radiotracer” has its’ conventional meaning and refers to a radiopharmaceutical used to trace a physiological or biological process without affecting it. The term “radiopharmaceutical” has its’ conventional meaning and refers to a radiolabelled compound administered to the mammalian body *in vivo* for the

purpose of imaging or therapy. During chromatographic purification, such as when loaded and hence concentrated into a small volume at the top of an SPE column, the radiotracer may transiently be exposed to very high radioactive concentration (“RAC”). Thus, radiotracers which otherwise appear radiostable, may exhibit  
5 instability with consequent loss of radiochemical purity (“RCP”) and/or radiochemical yield during attempted purification.

By the term “radioprotectant” is meant a compound which inhibits degradation reactions, such as redox processes, by trapping highly-reactive free radicals, such as  
10 oxygen-containing free radicals arising from the radiolysis of water. The radioprotectants of the present invention is suitably chosen from *para*-aminobenzoic acid (i.e. 4-aminobenzoic acid) and salts thereof with a biocompatible cation. By the term “biocompatible cation” is meant a positively charged counterion which forms a salt with an ionised, negatively charged group, where said positively charged  
15 counterion is also non-toxic and hence suitable for administration to the mammalian body, especially the human body. Examples of suitable biocompatible cations include: the alkali metals sodium or potassium; the alkaline earth metals calcium and magnesium; and the ammonium ion. Preferred biocompatible cations are sodium and potassium, most preferably sodium.

20 The “biocompatible carrier” is a fluid, especially a liquid, in which the radioconjugate can be suspended or preferably dissolved, such that the composition is physiologically tolerable, i.e. can be administered to the mammalian body without toxicity or undue discomfort. The biocompatible carrier is suitably an injectable carrier liquid such as  
25 sterile, pyrogen-free water for injection; an aqueous solution such as saline (which may advantageously be balanced so that the final product for injection is isotonic); an aqueous buffer solution comprising a biocompatible buffering agent (e.g. phosphate buffer); an aqueous solution of one or more tonicity-adjusting substances (e.g. salts of plasma cations with biocompatible counterions), sugars (e.g. glucose or sucrose),  
30 sugar alcohols (e.g. sorbitol or mannitol), glycols (e.g. glycerol), or other non-ionic polyol materials (e.g. polyethyleneglycols, propylene glycols and the like). Preferably the biocompatible carrier is pyrogen-free water for injection, isotonic saline or phosphate buffer.

By the phrase “in a form suitable for mammalian administration” is meant a composition which is sterile, pyrogen-free, lacks compounds which produce toxic or adverse effects, and is formulated at a biocompatible pH (approximately pH 4.0 to 10.5). Such compositions lack particulates which could risk causing emboli *in vivo*,  
5 and are formulated so that precipitation does not occur on contact with biological fluids (e.g. blood). Such compositions also contain only biologically compatible excipients, and are preferably isotonic.

By the term “peptide” is meant a compound comprising two or more amino acids, as  
10 defined below, linked by a peptide bond (ie. an amide bond linking the amine of one amino acid to the carboxyl of another).

By the term “amino acid” is meant an *L*- or *D*-amino acid, amino acid analogue (eg. naphthylalanine) or amino acid mimetic which may be naturally occurring or of  
15 purely synthetic origin, and may be optically pure, i.e. a single enantiomer and hence chiral, or a mixture of enantiomers. Conventional 3-letter or single letter abbreviations for amino acids are used herein. Preferably the amino acids of the present invention are optically pure.

20 By the term “metabolism inhibiting group” ( $M^{IG}$ ) is meant a biocompatible group which inhibits or suppresses enzyme, especially peptidase (e.g. carboxypeptidase), metabolism of the cMBP at either the amino terminus or carboxy terminus. Such groups are particularly important for *in vivo* applications since otherwise rapid metabolism would be expected with consequent loss of selective binding affinity, and  
25 are well known to those skilled in the art and are suitably chosen from, for the peptide amine terminus:

N-acylated groups  $-NH(C=O)R^G$  where the acyl group  $-(C=O)R^G$  has  $R^G$  chosen  
from:  $C_{1-6}$  alkyl,  $C_{3-10}$  aryl groups or comprises a polyethyleneglycol (PEG) building  
30 block. Preferred such amino terminus  $M^{IG}$  groups are acetyl, benzyloxycarbonyl or trifluoroacetyl, most preferably acetyl.

Suitable metabolism inhibiting groups for the peptide carboxyl terminus include: carboxamide, *tert*-butyl ester, benzyl ester, cyclohexyl ester, amino alcohol or a polyethyleneglycol (PEG) building block. A suitable  $M^{IG}$  group for the carboxy

terminal amino acid residue of the cMBP is where the terminal amine of the amino acid residue is *N*-alkylated with a C<sub>1-4</sub> alkyl group, preferably a methyl group. Preferred such M<sup>IG</sup> groups are carboxamide or PEG, most preferred such groups are carboxamide.

5

The radiotracer and biocompatible carrier are supplied in a suitable vial or vessel which comprises a sealed container which permits maintenance of sterile integrity and/or radioactive safety, plus optionally an inert headspace gas (e.g. nitrogen or argon), whilst permitting addition and withdrawal of solutions by syringe or cannula.

10

A preferred such container is a septum-sealed vial, wherein the gas-tight closure is crimped on with an overseal (typically of aluminium). The closure is suitable for single or multiple puncturing with a hypodermic needle (e.g. a crimped-on septum seal closure) whilst maintaining sterile integrity. Such containers have the additional advantage that the closure can withstand vacuum if desired (eg. to change the

15

headspace gas or degas solutions), and withstand pressure changes such as reductions in pressure without permitting ingress of external atmospheric gases, such as oxygen or water vapour.

Preferred multiple dose containers comprise a single bulk vial which contains multiple patient doses, whereby single patient doses can thus be withdrawn into clinical grade syringes at various time intervals during the viable lifetime of the preparation to suit the clinical situation. Pre-filled syringes are designed to contain a single human dose, or "unit dose" and are therefore preferably a disposable or other syringe suitable for clinical use.

25

The radiopharmaceutical composition may contain additional optional excipients such as: an antimicrobial preservative, pH-adjusting agent, filler, solubiliser or osmolality adjusting agent. By the term "filler" is meant a pharmaceutically acceptable bulking agent which may facilitate material handling during production and lyophilisation.

30

Suitable fillers include inorganic salts such as sodium chloride, and water soluble sugars or sugar alcohols such as sucrose, maltose, mannitol or trehalose.

By the term "solubiliser" is meant an additive present in the composition which increases the solubility of the agent of interest in the solvent. A preferred such

solvent is aqueous media, and hence the solubiliser preferably improves solubility in water. Suitable such solubilisers include: C<sub>1-4</sub> alcohols; glycerine; polyethylene glycol (PEG); propylene glycol; polyoxyethylene sorbitan monooleate; sorbitan monooleate; polysorbates; poly(oxyethylene)poly(oxypropylene)poly(oxyethylene) block copolymers (Pluronic<sup>TM</sup>); cyclodextrins (e.g. alpha, beta or gamma cyclodextrin, hydroxypropyl-β-cyclodextrin or hydroxypropyl-γ-cyclodextrin) and lecithin.


By the term “antimicrobial preservative” is meant an agent which inhibits the growth of potentially harmful micro-organisms such as bacteria, yeasts or moulds. The antimicrobial preservative may also exhibit some bactericidal properties, depending on the dosage employed. The main role of the antimicrobial preservative(s) of the present invention is to inhibit the growth of any such micro-organism in the pharmaceutical composition. The antimicrobial preservative may, however, also optionally be used to inhibit the growth of potentially harmful micro-organisms in one or more components of kits used to prepare said composition prior to administration. Suitable antimicrobial preservative(s) include: the parabens, i.e. methyl, ethyl, propyl or butyl paraben or mixtures thereof; benzyl alcohol; phenol; cresol; cetrимide and thiomersal. Preferred antimicrobial preservative(s) are the parabens.

The term “pH-adjusting agent” means a compound or mixture of compounds useful to ensure that the pH of the composition is within acceptable limits (approximately pH 4.0 to 10.5) for human or mammalian administration. Suitable such pH-adjusting agents include pharmaceutically acceptable buffers, such as tricine, phosphate or TRIS [i.e. *tris*(hydroxymethyl)aminomethane], and pharmaceutically acceptable bases such as sodium carbonate, sodium bicarbonate or mixtures thereof. When the composition is employed in kit form, the pH adjusting agent may optionally be provided in a separate vial or container, so that the user of the kit can adjust the pH as part of a multi-step procedure.

#### Preferred features.

In the radiopharmaceutical composition of the first aspect, Z<sup>1</sup> is preferably acetyl and Z<sup>2</sup> is preferably a primary amide.

The  $^{18}\text{F}$  is preferably attached to the cMBP *via* an oxime linkage, more preferably to an aminoxy-functionalised cMBP. The term “aminoxy-functionalised” means that the cMBP is functionalised with, or has conjugated thereto, an aminoxy group. The term  
 5 “aminoxy group” has its conventional meaning, and refers to a substituent of formula  $-\text{O}-\text{NH}_2$ , preferably  $-\text{CH}_2-\text{O}-\text{NH}_2$ . The radiotracer of the first aspect is preferably of Formula II:



(II).

10 where conventional single letter amino acid abbreviations are used.

The 4-aminobenzoic acid concentration in the composition of the first aspect is preferably 1.5 to 2.5 mg/mL, more preferably 1.8 to 2.2 mg/mL, most preferably about  
 15 2.0 mg/mL.

The ethanol concentration in the composition of the first aspect is preferably 6.5 to 8.5% v/v.

The aqueous component of the biocompatible carrier in the composition of the first  
 20 aspect is preferably a buffer solution of pH 6-8, more preferably a phosphate buffer.

In the radiopharmaceutical composition of the first aspect, preferably at least 90% of the  $^{18}\text{F}$  radioactive content is the radiotracer of Formula (I), and less than 10% of said content is the total of  $[\text{}^{18}\text{F}]$ -4-fluorobenzaldehyde and  $[\text{}^{18}\text{F}]$ -4-fluorobenzonitrile.  
 25 More preferably, at least 92% of the  $^{18}\text{F}$  radioactive content is the radiotracer of Formula (I), and less than 5% of said content is the total of  $[\text{}^{18}\text{F}]$ -4-fluorobenzaldehyde and  $[\text{}^{18}\text{F}]$ -4-fluorobenzonitrile. Fluorobenzonitrile is the


compound F-Ph-CN, where Ph is 1,4-phenylene. These radioactive impurities arise from previously unrecognised in-process radiolysis of the  $^{18}\text{F}$ -labelled cMBP of the invention, and their control gives improved radiopharmaceutical compositions.

- 5 The radiopharmaceutical compositions of the first aspect can be prepared as described in the second aspect (below).

In a second aspect, the present invention provides a method of preparation of the  
10 radiopharmaceutical composition of the first aspect, which comprises:

(A) provision of a single use cassette which comprises:

- (i) a first non-radioactive precursor, capable of reacting with  $^{18}\text{F}$ -fluoride to give  $^{18}\text{F}$ -fluorobenzaldehyde;  
 (ii) a second non-radioactive precursor of Formula III, capable of reacting with  
 15  $^{18}\text{F}$ -fluorobenzaldehyde to give the radiotracer of Formula II as defined in the first aspect:



- 20 (iii) a reverse phase solid phase extraction column;  
 (iv) a supply of the radioprotectant as defined in the first aspect;  
 (v) a reaction vessel;  
 (vi) suitable solvents;  
 (B) reaction of the first precursor with  $^{18}\text{F}$ -fluoride to give  $^{18}\text{F}$ -fluorobenzaldehyde;  
 25 (C) reaction of the  $^{18}\text{F}$ -fluorobenzaldehyde from step (B) with the second precursor to give the radiotracer of Formula II;

(D) addition of said radioprotectant to the radiotracer of Formula II from step (C) to give a radiotracer solution;

(E) purification of the radiotracer solution from step (D) using said reverse phase solid phase extraction column;

5 (F) optionally diluting the purified [ $^{18}\text{F}$ ]-radiotracer from step (E) with a biocompatible carrier;

(G) aseptic filtration of the optionally diluted solution from step (F) to give said radiopharmaceutical composition;

10 wherein said cassette fits removably and interchangeably onto an automated synthesizer apparatus and said automated synthesizer apparatus is used to carry out at least steps (B)-(E).

Preferred embodiments of the radiotracer and radioprotectant in the second aspect are as described in the first aspect (above).

15

The term “reverse phase” refers to “reverse phase chromatographic purification”, which has its conventional meaning, and refers to chromatography where the stationary phase is lipophilic and the mobile phase is hydrophilic, typically involving aqueous media. The chromatographic technique of the present invention is solid  
20 phase extraction (SPE) using either an SPE column, sometimes called an ‘SPE cartridge’. Such SPE columns have the advantage that they are single use, i.e. disposable, so there is no risk of cross-contamination with other radiotracers. The reverse phase SPE cartridge of the second aspect preferably has a carbon load of 2.7 to 17%, and and is more preferably a C18 SPE cartridge, most preferably a tC18 SPE  
25 cartridge. Reverse phase SPE cartridges suitable for use in the present invention can be obtained from Waters Limited (730-740 Centennial Court, Centennial Park, Elstree, Hertfordshire, UK).

30

In order to obtain radiopharmaceutical compositions, the method of the second aspect is carried out using aseptic manufacture techniques in which the steps are carried out using an automated synthesizer apparatus. By the term “automated synthesizer” is meant an automated module based on the principle of unit operations as described by Satyamurthy *et al* [Clin.Positr.Imag., 2(5), 233-253 (1999)]. The term ‘unit operations’ means that complex processes are reduced to a series of simple operations

or reactions, which can be applied to a range of materials. Such automated synthesizers are preferred for the method of the present invention especially when a radiopharmaceutical composition is desired. They are commercially available from a range of suppliers [Satyamurthy *et al*, above], including: GE Healthcare; CTI Inc; Ion Beam Applications S.A. (Chemin du Cyclotron 3, B-1348 Louvain-La-Neuve, Belgium); Raytest (Germany) and Bioscan (USA).

Commercial automated synthesizers also provide suitable containers for the liquid radioactive waste generated as a result of the radiopharmaceutical preparation.

Automated synthesizers are not typically provided with radiation shielding, since they are designed to be employed in a suitably configured radioactive work cell. The radioactive work cell provides suitable radiation shielding to protect the operator from potential radiation dose, as well as ventilation to remove chemical and/or radioactive vapours. The automated synthesizer preferably comprises a cassette.

By the term “cassette” is meant a unit piece of apparatus designed such that the whole unit fits removably and interchangeably onto an automated synthesizer apparatus (as defined above), in such a way that mechanical movement of moving parts of the synthesizer controls the operation of the cassette from outside the cassette, i.e. externally. Suitable cassettes comprise a linear array of valves, each linked to a port where reagents or vials can be attached, by either needle puncture of an inverted septum-sealed vial, or by gas-tight, marrying joints. Each valve has a male-female joint which interfaces with a corresponding moving arm of the automated synthesizer. External rotation of the arm thus controls the opening or closing of the valve when the cassette is attached to the automated synthesizer. Additional moving parts of the automated synthesizer are designed to clip onto syringe plunger tips, and thus raise or depress syringe barrels.

The cassette is versatile, typically having several positions where reagents can be attached, and several suitable for attachment of syringe vials of reagents or chromatography cartridges (e.g. solid phase extraction or SPE). The cassette always comprises a reaction vessel. Such reaction vessels are preferably 1 to 10 cm<sup>3</sup>, most preferably 2 to 5 cm<sup>3</sup> in volume and are configured such that 3 or more ports of the cassette are connected thereto, to permit transfer of reagents or solvents from various

ports on the cassette. Preferably the cassette has 15 to 40 valves in a linear array, most preferably 20 to 30, with 25 being especially preferred. The valves of the cassette are preferably each identical, and most preferably are 3-way valves. The cassettes are designed to be suitable for radiopharmaceutical manufacture and are therefore manufactured from materials which are of pharmaceutical grade and ideally also are resistant to radiolysis.

Suitable automated synthesizers of the present invention comprise a disposable or single use cassette which comprises all the reagents, reaction vessels and apparatus necessary to carry out the preparation of a given batch of radiofluorinated radiopharmaceutical. The cassette means that the automated synthesizer has the flexibility to be capable of making a variety of different radiopharmaceuticals with minimal risk of cross-contamination, by simply changing the cassette. The cassette approach also has the advantages of: simplified set-up hence reduced risk of operator error; improved GMP (Good Manufacturing Practice) compliance; multi-tracer capability; rapid change between production runs; pre-run automated diagnostic checking of the cassette and reagents; automated barcode cross-check of chemical reagents *vs* the synthesis to be carried out; reagent traceability; single-use and hence no risk of cross-contamination, tamper and abuse resistance.

20

In the method of the second aspect, the automated synthesizer apparatus is preferably used to carry out steps (B)-(G).

The "first non-radioactive precursor" is designed to react with [<sup>18</sup>F]-fluoride to give [<sup>18</sup>F]-fluorobenzaldehyde in a single step. Suitable such precursors are known in the art. A preferred such precursor is Precursor 1 (below).

25

The second non-radioactive precursor is of Formula (III) as shown above. Such aminoxy functionalised peptides can be prepared by the methods of Poethko *et al* [J.Nucl.Med., 45, 892-902 (2004)], Schirmacher *et al* [Bioconj.Chem., 18, 2085-2089 (2007)], Indrevoll *et al* [Bioorg.Med.Chem.Lett, 16, 6190-6193 (2006)], Glaser *et al* [Bioconj. Chem., 19, 951-957 (2008)] or Dall'Angelo *et al* [Org.Biomol.Chem., 11, 4551-4558 (2013)]. The aminoxy group may optionally be conjugated in two steps. First, the *N*-protected aminoxy carboxylic acid or *N*-protected aminoxy

30

activated ester is conjugated to the peptide (e.g. *via* conjugation to the amine group of a Lys residue, or *via* conventional solid phase synthesis). Second, the intermediate *N*-protected aminoxy functionalised peptide is deprotected to give the desired product [see Solbakken and Glaser papers cited above]. *N*-protected aminoxy carboxylic acids such as Boc-aminoxyacetic acid [Boc-NH-O-CH<sub>2</sub>(C=O)OH] and Eei-N-O-CH<sub>2</sub>(C=O)OH are commercially available, e.g. from Sigma-Aldrich, Novabiochem and IRIS.

The term “protected” refers to the use of a protecting group. By the term “protecting group” is meant a group which inhibits or suppresses undesirable chemical reactions, but which is designed to be sufficiently reactive that it may be cleaved from the functional group in question under mild enough conditions that do not modify the rest of the molecule. After deprotection the desired product is obtained. Amine protecting groups are well known to those skilled in the art and are suitably chosen from: Boc (where Boc is *tert*-butyloxycarbonyl); Eei (where Eei is ethoxyethylidene); Fmoc (where Fmoc is fluorenylmethoxycarbonyl); trifluoroacetyl; allyloxycarbonyl; Dde [i.e. 1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl] or Npys (i.e. 3-nitro-2-pyridine sulfenyl). The use of further protecting groups are described in *Protective Groups in Organic Synthesis*, 4<sup>th</sup> Edition, Theodor W. Greene and Peter G. M. Wuts, [Wiley Blackwell, (2006)]. Preferred amine protecting groups are Boc and Eei, most preferably Eei.

In the method of the second aspect, the radiotracer solution of step (D) comprises said radiotracer in aqueous acetonitrile of 5 to 25% v/v acetonitrile content. The radiotracer solution of step (D) preferably comprises ethanol, and more preferably comprises both acetonitrile and ethanol. Ethanol has potentially multiple roles, since it can function as: a water-miscible organic solvent (as defined above); a radioprotectant or radiostabiliser; a ‘biocompatible carrier’ (as defined above; and as an antimicrobial preservative (as defined above. The present inventors have found that the combination of the ‘radioprotectant’ (as defined above) and ethanol is most effective to stabilise the radiotracers of the invention against radiolysis. The ethanol content of the radiotracer solution is preferably 0.5 to 5% v/v ethanol.

The purification step (E) removes species which remain bound to the SPE column – e.g. very lipophilic species or any particulates. Step (E) also removes hydrophilic impurities which exhibit low affinity for the SPE column stationary phase – and are thus removed in the loading and washing steps. Such hydrophilic impurities include  
5 any salts or ionic species (such as fluoride ion); catalysts (such as aniline); as well as the water-miscible organic solvent(s) from the radiotracer solution.

The radiotracer typically results from the conjugation of  $^{18}\text{F}$ -fluorobenzaldehyde (or similar) to an aminoxy-functionalised biological targeting moiety precursor, the  
10 conjugated fluorobenzaldehyde moiety confers additional lipophilicity to the conjugate. Hence, the radiotracer will tend to be retained on a reverse-phase SPE column, whereas the non-radioactive precursor itself (being more hydrophilic) will tend to be removed in the loading step and washing steps. Washing steps are also important to remove water-miscible organic solvent. In this way, the radiotracer  
15 solution is purified to remove unwanted non-radioactive impurities based on the biological targeting moiety which, if present, might compete with the radiotracer for biological sites of interest *in vivo*. Any more hydrophilic  $^{18}\text{F}$ -labelled, radioactive impurities will tend to be removed in a similar way. Thus, the initial level of Compound 2 in a preparation was 5 mg, which was reduced to ca. 200  $\mu\text{g}$  (0.2 mg) in  
20 the purified radiotracer.

The SPE cartridge of the second aspect is preferably conditioned prior to use by treating first with a water-miscible organic solvent, then with a conditioning solution. Said water-miscible organic solvent is preferably ethanol, and said conditioning  
25 solution is suitably a 40-60% aqueous/water-miscible organic solvent mixture, more preferably 50% aqueous ethanol.

The radiotracer of step (C) and/or the radiotracer solution of step (D) are preferably cooled to a temperature range of 18 to 37 °C, preferably 18 to 30 °C.  
30

The purification step (E) of the second aspect is preferably carried out as follows:

- (i) passing the radiotracer solution from step (D) through said reverse phase SPE cartridge, wherein the radiotracer is retained on said SPE cartridge;

(ii) washing the SPE cartridge from step (i) one or more times with a wash solution which comprises an aqueous acetonitrile solution of said radioprotectant of 15 to 25% v/v acetonitrile content;

5 (iii) washing the SPE cartridge from step (ii) one or more times with water or aqueous buffer solution;

(iv) eluting the washed SPE cartridge of step (ii) or (iii) with an elution solvent which comprises said radioprotectant in an aqueous ethanol solution having an ethanol content of 35 to 80 % v/v, wherein the eluent comprises purified radiotracer in said elution solvent.

10

The term "aqueous acetonitrile solution of said radioprotectant of 15 to 25% v/v acetonitrile content" refers to an aqueous solution (e.g. water itself, saline, an aqueous buffer or mixtures thereof), mixed with acetonitrile and possibly also ethanol (see below). Acetonitrile has the advantages that it is a good solvent for the radiotracer, is  
15 neither acidic nor basic, is relatively unreactive and thus compatible with a wide range of functional groups, and is highly miscible with water so that it is easily and completely removed (or at least down to ppm levels) by the washing of the SPE column in method steps (iii) and (iv). Acetonitrile was found to be the most efficient solvent for removal of impurities in the radiotracer, including aniline. The acetonitrile  
20 content of the radiotracer solution and wash solution preferably does not exceed 25% v/v, since higher levels risk loss of radiotracer product by elution from the SPE column. The acetonitrile content of the wash solution is preferably 18-22 % v/v, more preferably 20-21% v/v.

25 The elution solvent of step (iv) preferably comprises 35-70 % v/v aqueous ethanol, more preferably 40-60 % v/v aqueous ethanol, most preferably 48-52% aqueous ethanol and especially preferably 50% aqueous ethanol.

The pH of the aqueous component of the radiotracer solution, wash solution, and  
30 elution solvent is preferably 7.5 to 8.5. That is preferably achieved using buffer solutions, more preferably phosphate buffer.

When the radioprotectant is sodium 4-aminobenzoate, a preferred concentration in the radiotracer solution is 5 mg/mL, and a preferred concentration in the wash solution

and elution solvent is 2.5 mg/mL. An especially preferred radiotracer solution comprises 5 mg/mL sodium 4-aminobenzoate, 2% ethanol in a mixture of 79 g phosphate-buffered saline (pH 7.5) and 16.5 g acetonitrile. An especially preferred wash solution comprises 5 mg/mL sodium 4-aminobenzoate in phosphate-buffered saline (pH 7.5).

The SPE cartridge is preferably flushed between purification steps with air instead of nitrogen. Thus, the present inventors have found that the radioprotectant 4-aminobenzoic acid functions more effectively in the presence of air, as opposed to the situation where oxygen is excluded.

The purified radiotracer of step (iv) thus preferably contains 4-aminobenzoic acid, or a salt thereof with a biocompatible cation as radioprotectant, in 35-70% aqueous ethanol. For radiopharmaceutical applications, that is preferably diluted with an aqueous biocompatible carrier to give a final ethanol content of 0.1 to 10% v/v.

The method of the second aspect preferably further comprises:

- (H) dispensing the [<sup>18</sup>F]-radiotracer radiopharmaceutical composition of step (G) into one or more syringes.

In a third aspect, the present invention provides a single use cassette as defined in the second aspect. Preferred embodiments of the cassette in the third aspect are as described in the second aspect (above).

In a fourth aspect, the present invention provides the use of an automated synthesizer apparatus as defined in the second aspect, to carry out the method of preparation of the second aspect. Preferred embodiments of the synthesizer and associated cassette in the fourth aspect are as described in the second aspect (above).

In a fifth aspect, the present invention provides the use of the cassette as defined in the second and third aspects, to carry out the method of preparation of the second aspect.

Preferred embodiments of the synthesizer and associated cassette in the fifth aspect are as described in the second aspect (above).

Description of the Figures.

Figure 1 shows the radiation elution profile of Compound 3 through an SPE column, during the loading, washing and elution process using six radioactivity detectors positioned at various places on the FASTlab.

Figure 2 shows a FastLab cassette configuration for the automated radiosynthesis and automated purification of Compound 3.

- 10 The invention is illustrated by the non-limiting Examples detailed below. Example 1 provides the synthesis of a c-Met targeting peptide of the invention (“Peptide 1”). Example 2 provides the synthesis of an aminoxy-functionalised Peptide 1 (“Compound 1”), wherein the aminoxy functional group is protected with a protecting group (Eei), and subsequent deprotection to give Compound 2. Example 3 provides the radiosynthesis of [<sup>18</sup>F]-fluorobenzaldehyde. Example 4 is a comparative Example, which provides the radiosynthesis of the <sup>18</sup>F-labelled conjugate Compound 3, without the methodology of the present invention. The RCP in this case is relatively low (79%) at the end of synthesis.
- 15
- 20 Example 5 provides an analysis of the identity and time-course of the radiochemical impurities in low RCP Compound 3 purified according to Example 4. This provides evidence that in-process radiolysis during attempted chromatographic purification was responsible for the low RCP. Example 5 provides information on the movement of radioactivity through the SPE column during SPE purification, demonstrating that the RAC is over 45 GBq/mL during the SPE process. This very high, but time-bound RAC, is also indicative of in-process radiolysis.
- 25





Example 7 provides an automated synthesis and purification of Compound 3, using an automated synthesizer and cassette. A significant increase in EOS yield was achieved by making up a MeCN/PBS purification solution containing 2.5 mg/Na-pABA, but the EOS RCP was still low, and vulnerable to high RAC (RCP= 89% when a RAC of 660 MBq/mL, RCP =85% when a RAC of 844 MBq/ml in a 25 mL formulation). A high RAC at EOS indicates yet higher RAC on the cartridge during the later stages of the purification process. The RCP was improved further by increasing the Na-pABA

30

content of the radiotracer solution to 5 mg/mL to 89-91%. Yet further improvements in RCP were obtained by adding HCl to the pABA wash solution to make it pH 4. The addition of ethanol (2%) to the radiotracer solution and wash solution resulted in a further improvement in RCP to >92%. The process of Example 7 removes 85% of peptide-related impurities and essentially all of the aniline (20 µg remaining out of 100,000 µg aniline present in the crude product before purification). The addition of the pABA and ethanol did not adversely affect the performance of the SPE purification with respect to the removal of chemical impurities.

10

Compounds of the Invention.

Name	Structure
Peptide 1	Disulfide bridges at Cys4-16 and Cys6-14; Ac-Ala-Gly-Ser-Cys-Tyr-Cys-Ser-Gly-Pro-Pro-Arg-Phe-Glu-Cys-Trp-Cys-Tyr-Glu-Thr-Glu-Gly-Thr-Gly-Gly-Gly-Lys-NH <sub>2</sub> or Ac-AGSCYCSGPPRFECWCYETEGTGGGK-NH <sub>2</sub>
Compound 1	
Compound 2	
Compound 3	
Precursor 1	

where:

Compounds 1, 2 and 3 are functionalised at the epsilon amine group of the carboxy terminal Lys of Peptide 1;

15

alternative stereochemistry at the oxime bond is possible, but not shown.


Abbreviations.

Conventional single letter or 3-letter amino acid abbreviations are used.

- Ac: Acetyl  
Acm: Acetamidomethyl  
5 ACN or MeCN: Acetonitrile.  
AcOH: Acetic acid.  
Boc: *tert*-Butyloxycarbonyl.  
BTM: biological targeting moiety.  
tBu: *tertiary*-butyl  
10 DCM: Dichloromethane  
DIPEA: *N,N*-Diisopropylethyl amine  
DMF: Dimethylformamide  
DMSO: Dimethylsulfoxide  
Eei: ethoxyethylidene;  
15 Eei-AOAc-OSu: *N*-(1-Ethoxyethylidene)-2-aminoxyacetic acid *N*-hydroxysuccinimidyl ester;  
EOS: end of synthesis;  
FBA: 4-fluorobenzaldehyde;  
Fmoc: 9-Fluorenylmethoxycarbonyl;  
20 HBTU: *O*-Benzotriazol-1-yl-*N,N,N',N'*-tetramethyluronium hexafluorophosphate;  
HPLC: High performance liquid chromatography;  
MW: molecular weight;  
NHS: *N*-hydroxy-succinimide;  
NMM: *N*-Methylmorpholine;  
25 NMP: 1-Methyl-2-pyrrolidinone;  
Pbf: 2,2,4,6,7-Pentamethyldihydrobenzofuran-5-sulfonyl;  
RAC: radioactive concentration.  
RCP: radiochemical purity.  
RP-HPLC: reverse-phase high performance liquid chromatography;  
30 tBu: *tert*-butyl;  
TFA: Trifluoroacetic acid;  
THF: Tetrahydrofuran;  
TIS: Triisopropylsilane;  
Trt: Trityl.

**Example 1: Synthesis of Peptide 1.**Step (a): synthesis of protected precursor linear peptide.

The precursor linear peptide has the structure:



The peptidyl resin H-Ala-Gly-Ser(tBu)-Cys(Trt)-Tyr(tBu)-Cys(Acm)-Ser(tBu)-Gly-  
Pro-Pro-Arg(Pbf)-Phe-Glu(OtBu)-Cys(Acm)-Trp(Boc)-Cys(Trt)-Tyr(tBu)-  
10 Glu(OtBu)-Thr( $\psi^{\text{Me,Me}}$ pro)-Glu(OtBu)-Gly-Thr(tBu)-Gly-Gly-Gly-Lys(Boc)-Polymer  
was assembled on an Applied Biosystems 433A peptide synthesizer using Fmoc  
chemistry starting with 0.1 mmol Rink Amide Novagel resin. An excess of 1 mmol  
pre-activated amino acids (using HBTU) was applied in the coupling steps. Glu-Thr  
pseudoproline (Novabiochem 05-20-1122) was incorporated in the sequence. The  
resin was transferred to a nitrogen bubbler apparatus and treated with a solution of  
15 acetic anhydride (1 mmol) and NMM (1 mmol) dissolved in DCM (5 mL) for 60 min.  
The anhydride solution was removed by filtration and the resin washed with DCM  
and dried under a stream of nitrogen.

The simultaneous removal of the side-chain protecting groups and cleavage of the  
20 peptide from the resin was carried out in TFA (10 mL) containing 2.5 % TIS, 2.5 % 4-  
thiocresol and 2.5 % water for 2 hours and 30 min. The resin was removed by  
filtration, TFA removed *in vacuo* and diethyl ether added to the residue. The formed  
precipitate was washed with diethyl ether and air-dried affording 264 mg of crude  
peptide.

25 Purification by preparative HPLC (gradient: 20-30 % B over 40 min where A =  
H<sub>2</sub>O/0.1 % TFA and B = ACN/0.1 % TFA, flow rate: 10 mL/min, column:  
Phenomenex Luna 5 $\mu$  C18 (2) 250 x 21.20 mm, detection: UV 214 nm, product  
retention time: 30 min) of the crude peptide afforded 100 mg of pure Peptide 1 linear  
30 precursor. The pure product was analysed by analytical HPLC (gradient: 10-40 % B  
over 10 min where A = H<sub>2</sub>O/0.1 % TFA and B = ACN/0.1 % TFA, flow rate: 0.3  
mL/min, column: Phenomenex Luna 3 $\mu$  C18 (2) 50 x 2 mm, detection: UV 214 nm,  
product retention time: 6.54 min). Further product characterisation was carried out  
using electrospray mass spectrometry (MH<sub>2</sub><sup>2+</sup> calculated: 1464.6, MH<sub>2</sub><sup>2+</sup> found: 1465.1).

Step (b): Formation of Monocyclic Cys4-16 disulfide bridge.

Cys4-16; Ac-Ala-Gly-Ser-Cys-Tyr-Cys(Acm)-Ser-Gly-Pro-Pro-Arg-Phe-Glu-Cys(Acm)-Trp-Cys-Tyr-Glu-Thr-Glu-Gly-Thr-Gly-Gly-Gly-Lys-NH<sub>2</sub>.

5 The linear precursor from step (a) (100 mg) was dissolved in 5 % DMSO/water (200 mL) and the solution adjusted to pH 6 using ammonia. The reaction mixture was stirred for 5 days. The solution was then adjusted to pH 2 using TFA and most of the solvent removed by evaporation *in vacuo*. The residue (40 mL) was injected in portions onto a preparative HPLC column for product purification.

10

Purification by preparative HPLC (gradient: 0 % B for 10 min, then 0-40 % B over 40 min where A = H<sub>2</sub>O/0.1 % TFA and B = ACN/0.1 % TFA, flow rate: 10 mL/min, column: Phenomenex Luna 5 $\mu$  C18 (2) 250 x 21.20 mm, detection: UV 214 nm, product retention time: 44 min) of the residue afforded 72 mg of pure Peptide 1

15

monocyclic precursor. The pure product (as a mixture of isomers P1 to P3) was analysed by analytical HPLC (gradient: 10-40 % B over 10 min where A = H<sub>2</sub>O/0.1 % TFA and B = ACN/0.1 % TFA, flow rate: 0.3 mL/min, column: Phenomenex Luna 3 $\mu$  C18 (2) 50 x 2 mm, detection: UV 214 nm, product retention time: 5.37 min (P1); 5.61 min (P2); 6.05 min (P3)). Further product characterisation was carried out using

20 electrospray mass spectrometry (MH<sub>2</sub><sup>2+</sup> calculated: 1463.6, MH<sub>2</sub><sup>2+</sup> found: 1464.1 (P1); 1464.4 (P2); 1464.3 (P3)).

Step (c): Formation of Second Cys6-14 disulfide bridge (Peptide 1).

The monocyclic precursor from step (b) (72 mg) was dissolved in 75 % AcOH/water  
25 (72 mL) under a blanket of nitrogen. 1 M HCl (7.2 mL) and 0.05 M I<sub>2</sub> in AcOH (4.8 mL) were added in that order and the mixture stirred for 45 min. 1 M ascorbic acid (1 mL) was added giving a colourless mixture. Most of the solvents were evaporated *in vacuo* and the residue (18 mL) diluted with water/0.1 % TFA (4 mL) and the product purified using preparative HPLC. Purification by preparative HPLC (gradient: 0 % B  
30 for 10 min, then 20-30 % B over 40 min where A = H<sub>2</sub>O/0.1 % TFA and B = ACN/0.1 % TFA, flow rate: 10 mL/min, column: Phenomenex Luna 5 $\mu$  C18 (2) 250 x 21.20 mm, detection: UV 214 nm, product retention time: 43-53 min) of the residue afforded 52 mg of pure Peptide 1. The pure product was analysed by analytical HPLC (gradient: 10-40 % B over 10 min where A = H<sub>2</sub>O/0.1 % TFA and B =  
35 ACN/0.1 % TFA, flow rate: 0.3 mL/min, column: Phenomenex Luna 3 $\mu$  C18 (2) 50 x

2 mm, detection: UV 214 nm, product retention time: 6.54 min). Further product characterisation was carried out using electrospray mass spectrometry ( $MH_2^{2+}$  calculated: 1391.5,  $MH_2^{2+}$  found: 1392.5).

5

**Example 2: Synthesis, Purification and Lyophilization of Compound 2.**

Peptide 1 (0.797 g) and Eei-AOAc-OSu (IRIS Biotech; 127 mg) were dissolved in DMF (12 mL). DIPEA (100  $\mu$ L) was added and the reaction mixture shaken for 26 min. A second aliquot of DIPEA (80  $\mu$ L) was added and the reaction mixture shaken  
10 for 2 hr. The reaction mixture was then diluted with 10% ACN/water/0.1 % ammonium acetate (40 mL), and the product purified by preparative HPLC using A = 0.1% TFA/water and B = ACN with gradient elution of 20-40% B over 40 min. The fractions containing pure products (these are a mixture of Compound 1 and Compound 2) were pooled in a flask and the flask flushed with argon. The solution  
15 was stirred overnight to afford complete removal of Eei protecting groups. The deprotected product was lyophilised affording 550 mg (69% yield) of Compound 2.

The pure product was analysed by analytical LC-MS (gradient: 10-40 % B over 5 min where A = H<sub>2</sub>O/0.1 % TFA and B = ACN TFA, flow rate: 0.6 mL/min, column:  
20 Phenomenex Luna 3 $\mu$  C18 (2) 20 x 2 mm, detection: UV 214 nm, product retention time: 3.00 min),  $MH_2^{2+}$  calculated: 1428.1,  $MH_2^{2+}$  found: 1427.9).

**Example 3: Radiosynthesis of [<sup>18</sup>F]-fluorobenzaldehyde (<sup>18</sup>F-FBA).**

[<sup>18</sup>F]-fluoride was produced using a GEMS PETtrace cyclotron with a silver target *via*  
25 the [<sup>18</sup>O](p,n) [<sup>18</sup>F] nuclear reaction. Total target volumes of 3.2 - 4.8 mL were used. The radiofluoride was trapped on a Waters QMA cartridge (pre-conditioned with carbonate), and the fluoride is eluted with a solution of Kryptofix<sub>2.2.2</sub>. (5.14 mg) and potassium bicarbonate (1.40 mg) in water (800  $\mu$ L) and acetonitrile (200  $\mu$ L).  
30 Nitrogen was used to drive the solution off the QMA cartridge to the reaction vessel. The [<sup>18</sup>F]-fluoride was dried for 9 minutes at 120 °C under a steady stream of nitrogen and vacuum. Trimethylammonium benzaldehyde triflate, [Precursor 1; Haka *et al*, J.Lab.Comp.Radiopharm., 27, 823-833 (1989)] (3.7 mg), in DMSO (2.0 mL) was

added to the dried [ $^{18}\text{F}$ ]-fluoride, and the mixture heated to 80 °C for 2 minutes to produce 4- $^{18}\text{F}$ -fluorobenzaldehyde.

5 **Example 4: Radiosynthesis of Compound 3 (Comparative Example).**

Compound 2 from Example 2 was radiolabelled with  $^{18}\text{F}$  using  $^{18}\text{F}$ -FBA from Example 3, then purified using a MCX+ SPE column, without the in-process radiostabilisation of the present invention, giving Compound 3 with an RCP of 79%.

10 **Example 5: Radiochemical Impurities in Low RCP Compound 3.**

The RCP of Compound 3 prepared as per Example 3 was studied as a function of time. The RCP did not drop further over time (up to 8 hours), showing that:

(i) Compound 3 is relatively radiostable at the RAC conditions existing at the end of the SPE process;

15 (ii) the RCP must already have been low at the end of the SPE process.

Analysis of Compound 3 from Example 4, i.e. without using the radiostabilisation methodology of the present invention and exhibiting low RCP (79%), found two radiolysis products to be the main contributors to the low RCP. These were identified  
20 by retention time on analytical HPLC, and comparison with the retention time of authentic samples of the non-radioactive analogues. These two radiolysis products are [ $^{18}\text{F}$ ]4-fluorobenzaldehyde (FBA) and [ $^{18}\text{F}$ ]4-fluorobenzonitrile (FPhCN), which together represented 12% of the radioactivity present in the low RCP Compound 3 preparation from Example 4.

25

These principal radiochemical impurities, which do not increase significantly with time, represent radiodegradation products of Compound 3, and in turn, in-process radiolysis.

30

**Example 6: SPE Elution Profile in the Purification of Compound 3.**

Six radioactivity detectors were positioned along a FastLab cassette, with Detector #6 positioned towards the bottom of the SPE column of a preparation according to Example 7. The movement of radioactivity during the loading, washing, and elution steps of the SPE purification process was followed in this way.

The results are shown in Figure 1. The crude product was shown to be trapped on the top of the SPE cartridge. As the purification proceeds, the radioactivity moved down the cartridge and towards the higher-numbered detectors, increasing their signal. This demonstrated that the radioactivity is not spread out over the entire cartridge, but concentrated in a tight band. During the purification, all the activity was concentrated into a volume of less than 1 mL, giving a RAC during purification (12-14 min) of 45,000 MBq/mL, i.e. 45 GBq/mL.

**Example 7: Automated Synthesis and Purification of Compound 3.**

A FastLab automated synthesizer (GE Healthcare Ltd) with cassette was used. The tC18 cartridge was obtained from Waters Limited (address as above). Precursor 1 was reacted with [<sup>18</sup>F]-fluoride on the Fastlab according to Example 3 to give [<sup>18</sup>F]-FBA. The [<sup>18</sup>F]-FBA was reacted subsequently on the FastLab with Compound 2 (aminoxy derivative of Peptide 1), to give crude Compound 3.

**Purification.**

The cassette configuration is given in Figure 2. Three external solvent vials are used on the cassette for the SPE purification:

Position 17 = Anhydrous ethanol;

Position 18 = Wash Solution of 5 mg/mL Na-pABA 2% EtOH in 79 g PBS/16.5g MeCN, and HCl to bring to pH 4;

Position 20 = Formulation Buffer of 34 mL PBS containing 80 mg Na-pABA.

Other cassette positions:

Position 21: Tubing to the tC18 cartridge in Position 22;

Position 22: tC18 cartridge (900 mg);

Position 23: Sterile filter.

FASTlab procedure.

In the following, P17 etc refers to Position 17 of the cassette. S2 and S3 refer to syringe 2 and syringe 3:

- 5 (i) the first part of the purification process was conditioning with full S2 fill with ethanol from P17, followed by a full S2 fill of MeCN/PBS solution from P18.
- (ii) crude Compound 3 in the aqueous ethanol solution from the conjugation step was diluted 1:1 with the formulation buffer from P20. This was done in two portions: half of the content of the crude volume from the reaction vessel was transferred to S2,  
10 and thereafter mixed with the same volume of formulation buffer from P20. This mixture was then slowly trapped onto the tC18 cartridge. After the first trapping, the same procedure was repeated with the remaining half of the crude.
- (iii) S2 was rinsed with water and thereafter a full fill of S2 with the MeCN wash solution from P18. The MeCN wash solution was slowly pushed through the tC18  
15 cartridge and to waste. This was repeated 5 more times - six such washes in total (but note that with Eei protecting group synthesis only a total of three washes are needed).
- (iv) the MeCN on the tC18 cartridge was removed by solvent exchange: first 2x full fill of S2 with the formulation buffer from P20 followed by one full fill of S2 with water from the water bag.
- 20 (v) the eluent was made by mixing of 3 mL ethanol from P17 and 3 mL of formulation buffer from P20 in S2. The first 1 mL of the eluent was passed through the tC18 and to waste, the following 4 mL eluent was passed through the tC18 and the purified Compound 3 product collected in S3. After elution the product was transferred out from the FASTlab and into the product vial through P19.


25

The radiochemical purity (RCP) in this case was 92%.

CLAIMS.

1. A radiopharmaceutical composition which comprises:

5 (i) a radiotracer which comprises a c-Met binding peptide of Formula I labelled with  $^{18}\text{F}$ :



(ii) a radioprotectant which comprises 4-aminobenzoic acid, or a salt thereof with a biocompatible cation;

10 (iii) a biocompatible carrier which comprises aqueous ethanol having an ethanol content of 0.1 to 10 % v/v;

in a form suitable for mammalian administration;

where:

cMBP is the c-Met binding peptide having the amino acid sequence:

15 Ala-Gly-Ser-Cys<sup>a</sup>-Tyr-Cys<sup>c</sup>-Ser-Gly-Pro-Pro-Arg-Phe-Glu-Cys<sup>d</sup>-Trp-Cys<sup>b</sup>-  
Tyr-Glu-Thr-Glu-Gly-Thr-Gly-Gly-Gly-Lys

wherein Cys<sup>a-d</sup> are each cysteine residues such that residues a and b as well as c and d are cyclised to form two separate disulfide bonds;

$Z^1$  is attached to the *N*-terminus of cMBP, and is  $\text{M}^{\text{IG}}$ ;

$Z^2$  is attached to the *C*-terminus of cMBP and is  $\text{M}^{\text{IG}}$ ;


20  $\text{M}^{\text{IG}}$  is independently a metabolism inhibiting group which is a biocompatible group which inhibits or suppresses *in vivo* metabolism of the cMBP peptide; the Lys residue of the cMBP is labelled with  $^{18}\text{F}$ .

25 2. The radiopharmaceutical composition of claim 1, where  $Z^1$  is acetyl and  $Z^2$  is a primary amide.

3. The radiopharmaceutical composition of claim 1 or 2, where the  $^{18}\text{F}$  is attached *via* an oxime linkage.

30





(III)

- (iii) a reverse phase solid phase extraction column;
- (iv) a supply of the radioprotectant as defined in claim 1;
- 5 (v) a reaction vessel;
- (vi) suitable solvents;
- (B) reaction of the first precursor with [<sup>18</sup>F]-fluoride to give [<sup>18</sup>F]-fluorobenzaldehyde;
- (C) reaction of the [<sup>18</sup>F]-fluorobenzaldehyde from step (B) with the second precursor to give the radiotracer of Formula II;
- 10 (D) addition of said radioprotectant to the radiotracer of Formula II from step (C);
- (E) purification of the radiotracer of Formula II from step (D) using said reverse phase solid phase extraction column;
- (F) optionally diluting the purified [<sup>18</sup>F]-radiotracer from step (E) with a biocompatible carrier;
- 15 (G) aseptic filtration of the optionally diluted solution from step (F) to give said radiopharmaceutical composition;
- wherein said cassette fits removably and interchangeably onto an automated synthesizer apparatus and said automated synthesizer apparatus is used to carry out at least steps (B)-(E).
- 20
8. The method of claim 7, where the automated synthesizer apparatus is used to carry out steps (B)-(G).
9. The method of claim 7 or 8, where the radiotracer solution of step (D) comprises said radiotracer in aqueous acetonitrile of 5 to 25% v/v acetonitrile content
- 25

10. The method of claim 9, where the radiotracer solution of step (D) further comprises 0.5 to 5% v/v ethanol.

11. The method of any one of claims 7 to 10, where the purification step (E) is  
5 carried out as follows:

(i) passing the radiotracer solution from step (D) through said reverse phase SPE cartridge, wherein the radiotracer is retained on said SPE cartridge;

(ii) washing the SPE cartridge from step (i) one or more times with a wash solution which comprises an aqueous acetonitrile solution of said  
10 radioprotectant of 15 to 25% v/v acetonitrile content;

(iii) washing the SPE cartridge from step (ii) one or more times with water or aqueous buffer solution;

(iv) eluting the washed SPE cartridge of step (ii) or (iii) with an elution solvent which comprises said radioprotectant in an aqueous ethanol solution having an  
15 ethanol content of 35 to 80 % v/v, wherein the eluent comprises purified radiotracer in said elution solvent.

12. The method of any one of claims 7 to 11, wherein the SPE cartridge is a C18 SPE cartridge.

20

13. The method of claim 12, where the elution solvent of step (iv) comprises 40-60 % v/v aqueous ethanol.

14. The method of any one of claims 7 to 13, which further comprises:

25 (H) dispensing the [<sup>18</sup>F]-radiotracer radiopharmaceutical composition of step (G) into one or more syringes.

15. A single use cassette as defined in any one of claims 7 to 13.

30 16. Use of an automated synthesizer apparatus as defined in any one of claims 7 to 13, to carry out the method of preparation of any one of claims 7 to 14.

17. Use of the cassette of claim 15 to carry out the method of preparation of any one of claims 7 to 14.

Figure 1: Radioactive Elution Profile During SPE.





Figure 2: Cassette Configuration.



INTERNATIONAL SEARCH REPORT

International application No  
PCT/EP2014/078609

A. CLASSIFICATION OF SUBJECT MATTER  
INV. A61K51/08 C07B59/00  
ADD.  
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED  
Minimum documentation searched (classification system followed by classification symbols)  
A61K C07B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
EPO-Internal, BIOSIS, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2012/087725 A1 (GE HEALTHCARE LTD [GB]; MEDI PHYSICS INC [US]; ENGELL TORGRIM [NO]; OS) 28 June 2012 (2012-06-28)	1-6
Y	examples claims	7-17
X	WO 2012/022676 A1 (GE HEALTHCARE LTD [GB]; IVESON PETER BRIAN [GB]; BHALLA RAJIV [GB]; IN) 23 February 2012 (2012-02-23)	1-6
Y	cited in the application page 13, last paragraph page 23 - page 24 examples; compound 3 claims	7-17
X	US 2009/274623 A1 (SMITH CLIFFORD L [GB] ET AL) 5 November 2009 (2009-11-05)	1-6
	page 22, left-hand column; example 33	
	-/--	

Further documents are listed in the continuation of Box C.

See patent family annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search  16 March 2015	Date of mailing of the international search report  07/04/2015
--	--

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer  Dullaart, Anwyn
--	---

## INTERNATIONAL SEARCH REPORT

International application No  
PCT/EP2014/078609

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2013/174909 A1 (GE HEALTHCARE LTD [GB]) 28 November 2013 (2013-11-28)	15-17
Y	figure 1 examples	7-14
	-----	
E	WO 2015/024983 A1 (GE HEALTHCARE LTD [GB]) 26 February 2015 (2015-02-26) examples compound 3	1-17
	-----	

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP2014/078609

## Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-17

Radiopharmaceutical composition comprising 18F-labelled c-Met binding peptide as defined, method for its preparation, single use cassette and automated synthesizer apparatus for this method.

1.1. claims: 1-6

Radiopharmaceutical composition comprising 18F-labelled c-Met binding peptide as defined.

1.2. claims: 7-17

Method for preparing the radiopharmaceutical as defined, single use cassette and automated synthesizer apparatus for this method.

---

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2014/078609

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
WO 2012087725	A1	28-06-2012	AU 2011349698 A1	25-07-2013
			CA 2822583 A1	28-06-2012
			CN 103370084 A	23-10-2013
			EP 2654798 A1	30-10-2013
			JP 2014508126 A	03-04-2014
			KR 20130132941 A	05-12-2013
			SG 191218 A1	31-07-2013
			US 2013274436 A1	17-10-2013
			WO 2012087725 A1	28-06-2012
			-----	
WO 2012022676	A1	23-02-2012	AU 2011290856 A1	14-03-2013
			CA 2807491 A1	23-02-2012
			CL 2013000483 A1	07-03-2014
			CN 103153350 A	12-06-2013
			EP 2605802 A1	26-06-2013
			JP 2013540702 A	07-11-2013
			KR 20130135242 A	10-12-2013
			NZ 606466 A	28-11-2014
			RU 2013105491 A	27-09-2014
			SG 187878 A1	28-03-2013
			US 2013149241 A1	13-06-2013
			WO 2012022676 A1	23-02-2012
-----				
US 2009274623	A1	05-11-2009	NONE	
-----				
WO 2013174909	A1	28-11-2013	CN 104302658 A	21-01-2015
			EP 2859010 A1	15-04-2015
			WO 2013174909 A1	28-11-2013
-----				
WO 2015024983	A1	26-02-2015	NONE	
-----				